NCT03215706 A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC Status COMPLETED Phase PHASE3
NCT03203876 A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors Status COMPLETED Phase PHASE1
NCT03203473 Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03203304 Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer Status TERMINATED Phase PHASE1
NCT03195478 A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors Status COMPLETED Phase PHASE1/PHASE2
NCT03190265 Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer Status COMPLETED Phase PHASE2
NCT03177239 Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) Status UNKNOWN Phase PHASE2
NCT03172624 Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer Status COMPLETED Phase PHASE2
NCT03168464 Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) Status TERMINATED Phase PHASE1/PHASE2
NCT03166397 Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients Status RECRUITING Phase PHASE2
NCT03165409 Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread Status COMPLETED Phase N/A
NCT03162731 Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer Status COMPLETED Phase EARLY_PHASE1
NCT03161756 Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma Status UNKNOWN Phase PHASE1/PHASE2
NCT03158129 Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer Status COMPLETED Phase PHASE2
NCT03153085 A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma Status COMPLETED Phase PHASE2
NCT03149159 Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab Status WITHDRAWN Phase PHASE2
NCT03146650 Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03143153 A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin Status COMPLETED Phase PHASE3
NCT03141177 A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT03138512 A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney Status COMPLETED Phase PHASE3